Evaluation of Epstein-Barr Virus Salivary Shedding in HIV/AIDS Patients and HAART Use: A Retrospective Cohort Study

Autor: Jing Hu, Hao Pei, Lvyin Hu, Junyang Yang, Ren Yong, Jiayin Shen, Yan Yan, Yongjia Ji, Hongzhou Lu, Lihua Huang, Jun Wang, Chen Renfang, Yuanwang Qiu
Rok vydání: 2018
Předmět:
Adult
Male
0301 basic medicine
Epstein-Barr Virus Infections
medicine.medical_specialty
Adolescent
Immunology
Population
Enzyme-Linked Immunosorbent Assay
HIV Infections
Virus
Serology
Young Adult
03 medical and health sciences
0302 clinical medicine
Medical microbiology
Acquired immunodeficiency syndrome (AIDS)
Seroepidemiologic Studies
Antiretroviral Therapy
Highly Active
Virology
medicine
Humans
030212 general & internal medicine
Saliva
education
Retrospective Studies
Acquired Immunodeficiency Syndrome
education.field_of_study
Transmission (medicine)
business.industry
Incidence (epidemiology)
virus diseases
Retrospective cohort study
Middle Aged
Viral Load
medicine.disease
CD4 Lymphocyte Count
Virus Shedding
030104 developmental biology
DNA
Viral
Molecular Medicine
Female
business
Research Article
Zdroj: Virologica Sinica. 33:227-233
ISSN: 1995-820X
1674-0769
DOI: 10.1007/s12250-018-0028-z
Popis: Little data is available on the evaluation of the occurrence rates of Epstein-Barr virus (EBV) in saliva and relationship with highly active antiretroviral therapy (HAART) use in HIV/AIDS patients in China. We conducted a retrospective cohort study of EBV serological tests for HIV/AIDS patients who were treated in the hospitals for infectious diseases in Wuxi and Shanghai, China from May 2016 to April 2017. The EBV-seropositive samples were identified by ELISA. EBV-specific primers and probes were used for the quantitative detection of viral DNA from saliva via quantitative real-time polymerase chain reaction. CD4 cell counts of the HIV/AIDS patients were detected by a flow cytometry. A total of 372 HIV/AIDS patients were ultimately selected and categorized for this retrospective cohort study. For EBV IgG and IgM, the HIV/AIDS HAART use (H) and non-HAART use (NH) groups had significantly higher seropositive rates than the HIV-negative control group. The HIV/AIDS (NH) group had the highest seropositive rate (IgG, 94.27%; IgM, 68.98%) and the highest incidence of EBV reactivation or infection. For salivary EBV DNA-positive rates and quantities, the HIV/AIDS (H) (73.69%) and the HIV/AIDS (NH) (100%) groups showed significantly higher values than the HIV-negative control group (35.79%, > twofold). Further, the salivary EBV DNA-negative population had significantly higher CD4 cell counts than the EBV DNA-positive population in the HIV/AIDS (H) group and the HIV/AIDS (NH) groups. Thus, HAART use is beneficial in decreasing the EBV salivary shedding in HIV/AIDS patients and indirectly decreases EBV transmission risk.
Databáze: OpenAIRE
Externí odkaz: